【US Stock Movement】Brain Regeneration Technology Plummets on October 12: Annual Losses Widen, No Revenue, High Valuation

Brain Regeneration Technology October 12 Major Drop Analysis

Keywords: increased annual loss, no revenue, high valuation

1. As of June 30, 2026, the company’s net loss for the fiscal year widened to $11.7 million, compared to $3.58 million in the same period last year; basic and diluted loss per share from continuing operations rose from $0.72 to $2.37. The company is still in the R&D stage and has yet to generate any revenue.

2. On October 7, 2026, the company submitted its annual report, disclosing that it remains in the early stage, with core products still facing patent applications, uncertainties regarding efficacy and commercialization, and its profit model not yet formed. Relevant financial report information continues to affect valuation assessments.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)